Alectinib | CH5424802;RO5424802;RG7853 | CH5424802,艾乐替尼 | ALK

首页 / / / ALK / Alectinib

艾乐替尼 /Alectinib {[allProObj[0].p_purity_real_show]}

货号：A264992 同义名： CH5424802,艾乐替尼 / CH5424802;RO5424802

Alectinib（CH5424802）是一种有效、选择性的口服ALK抑制剂，IC50为1.9 nM，Kd值为2.4 nM（以ATP竞争性方式），还以1 nM和3.5 nM的IC50值抑制ALK F1174L和ALK R1275Q。Alectinib显示出有效的中枢神经系统（CNS）渗透性。

Alectinib 化学结构
CAS号：1256580-46-7

Alectinib 3D分子结构
CAS号：1256580-46-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Alectinib 纯度/质量文件产品仅供科研

货号：A264992 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell, 2024, 101755. Ambeed. [ A399663 ]; • EMBO J., 2024. Ambeed. [ A295334 ]; • JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]; • JMC, 2024. Ambeed. [ A210558 , A1518164 ]; • Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]; 更多 >

ALK 亚型比较

产品名称	ALK ↓ ↑	其他靶点	纯度
ASP3026	+ ALK, IC50: 3.5 nM		99%+
ALK-IN-1	++++ ALK, IC50: 0.07 nM		98+%
Crizotinib	++++ ALK, IC50: 24 nM ROS1, Ki: <0.025 nM		98%
Entrectinib	✔		99%+
Brigatinib	+++ ALK, IC50: 0.37 nM ROS1, IC50: 1.9 nM	FLT3	98%
NVP-TAE 684	+ ALK, IC50: 3 nM		99%+
Alectinib	++ ALK, IC50: 1.9 nM ALK (F1174L), IC50: 3.5 nM		98%
Ceritinib	+++ ALK, IC50: 0.2 nM	Insulin Receptor,IGF-1R	98%
GSK1838705A	+++ ALK, IC50: 0.5 nM	Insulin Receptor,IGF-1R	99%
AZD-3463	++ ALK, Ki: 0.75 nM	IGF-1R	99%
Lorlatinib	++++ ALK (L1196M), Ki: 0.07 nM ROS1, Ki: <0.07 nM		98%
Repotrectinib	+ ALK(G1202R), IC50: 1.26 nM ALK(L1196M), IC50: 1.01 nM	Src	99%
Belizatinib	++ ALK, IC50: 0.7 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Alectinib 生物活性

靶点	ALK ALK, IC50:1.9 nM ALK (F1174L), IC50:3.5 nM
描述	ALK (anaplastic lymphoma kinase) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification or point mutation. Alectinib is a potent and selective ALK inhibitor with IC50 value of 1.9nM (measured by enzyme activity). Alectinib was preferentially efficacious against NCI-H2228 cells expressing EML4-ALK, but not ALK fusion-negative NSCLC cell lines, including HCC827 cells (EGFR exon 19 deletion), A549 cells (KRAS mutant), or NCIH522 cells (EGFR wild-type, KRAS wild-type, and ALK wildtype) in monolayer culture. Consistent with that, Alectinib can prevent autophosphorylation of ALK and thus resulted in substantial suppression of phosphorylation of STAT3 and AKT, but not of ERK1/2, in NCI-H2228 NSCLC cells expressing EML4-ALK, but not in ALK fusion-negative A549 cells. The potent inhibition of ALK kinase activity by Alectinib can also be observed in vivo. Oral administration of Alectinib caused dose-dependent decrease of pSTAT3-Tyr705 and pAKT-Ser473 in tumors from mice bearing NCI-H2228 cells at dose < 20mg/kg, with a significant decrease in the expression of STAT3 target genes, such as BCL3, NNMT, SOCS3 and BCL2L1, at dose of 6mg/kg. Administered CH5424802 orally once daily for 11 days at dose 2, 6 and 20mg/kg inhibited tumor growth dose-dependently, with decreased pALK-Tyr1604, in mice bearing NCI-H2228 but not A549. The maximum efficacy can be observed at dose of 60mg/kg for 3 weeks and a prolonged effect with no regrowth of tumor for 4 weeks in this model. Therapeutic efficacy of Alectinib on tumor regression can also be observed in models generated by implantation of KARPAS-299 ALCL cells and NB-1 neuroblastoma cells^[1].
作用机制	Alectinib acts in an ATP-competitive manner and blocks the L1196M gatekeeper mutation of ALK.^[1]

Alectinib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
22Rv1	~10 μM	Growth inhibitory assay		IC50>10,000 nM	21575866
Ba/F3	~1 μM	Function assay		suppresses phosphorylation of ERK and increases the abundance of BIM	25349307
BT-483	~10 μM	Growth inhibitory assay		IC50>10,000 nM	21575866
Calu-1	~10 μM	Growth inhibitory assay		IC50>10,000 nM	21575866

Alectinib 动物研究

Dose	Mice: min = 2 mg/kg, max = 20 mg/kg^[2] (p.o.); 25 mg/kg^[3] (i.p.)
Administration	p.o., i.p.

Alectinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03498521	Cancer of Unknown Primary Site	Phase 2	Recruiting	April 16, 2022	-
NCT01634763	Tumors Characterized by Geneti... 展开 >>c Alterations in Anaplastic Lymphoma Kinase (ALK) 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigative Site Sunto-gun, Shizuoka, Japan, 411-8777 Novartis Investigative Site Koto, Tokyo, Japan, 135-8550 Novartis Investigative Site Fukuoka, Japan, 811-1395 收起 <<
NCT03158389	Glioblastoma, Adult	Phase 1 Phase 2	Recruiting	September 30, 2024	Germany ... 展开 >> Charité Berlin, Neurosurgery Not yet recruiting Berlin, Germany Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic Not yet recruiting Bochum, Germany University Hospital Bonn, Neurology Clinic Not yet recruiting Bonn, Germany University Hospital Cologne, Neurosurgery Not yet recruiting Cologne, Germany University Hospital Dresden, Neurosurgery Not yet recruiting Dresden, Germany University Hospital Essen, Neurology Clinic Not yet recruiting Essen, Germany University Hospital Frankfurt, Neurooncology Not yet recruiting Frankfurt am Main, Germany University Hospital Heidelberg, Neurology Clinic Recruiting Heidelberg, Germany University Hospital Saarland, Neurosurgery Not yet recruiting Homburg, Germany University Hospital Mainz, Neurosurgery Not yet recruiting Mainz, Germany University Hospital Mannheim, Neurology Clinic Not yet recruiting Mannheim, Germany University Hospital Regensburg, Neurology Clinic Not yet recruiting Regensburg, Germany University Hospital Tuebingen, Neurooncology Not yet recruiting Tübingen, Germany 收起 <<

Alectinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.36mL

2.07mL

1.04mL

20.72mL

4.14mL

2.07mL

Alectinib 技术信息

CAS号	1256580-46-7
分子式	C₃₀H₃₄N₄O₂
分子量	482.617

别名	CH5424802,艾乐替尼 ;CH5424802;RO5424802;RG7853
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 2 mg/mL(4.14 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03498521	Cancer of Unknown Primary Site	Phase 2	Recruiting	April 16, 2022	-
NCT01634763	Tumors Characterized by Geneti... 展开 >>c Alterations in Anaplastic Lymphoma Kinase (ALK) 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Novartis Investigative Site Sunto-gun, Shizuoka, Japan, 411-8777 Novartis Investigative Site Koto, Tokyo, Japan, 135-8550 Novartis Investigative Site Fukuoka, Japan, 811-1395 收起 <<
NCT03158389	Glioblastoma, Adult	Phase 1 Phase 2	Recruiting	September 30, 2024	Germany ... 展开 >> Charité Berlin, Neurosurgery Not yet recruiting Berlin, Germany Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic Not yet recruiting Bochum, Germany University Hospital Bonn, Neurology Clinic Not yet recruiting Bonn, Germany University Hospital Cologne, Neurosurgery Not yet recruiting Cologne, Germany University Hospital Dresden, Neurosurgery Not yet recruiting Dresden, Germany University Hospital Essen, Neurology Clinic Not yet recruiting Essen, Germany University Hospital Frankfurt, Neurooncology Not yet recruiting Frankfurt am Main, Germany University Hospital Heidelberg, Neurology Clinic Recruiting Heidelberg, Germany University Hospital Saarland, Neurosurgery Not yet recruiting Homburg, Germany University Hospital Mainz, Neurosurgery Not yet recruiting Mainz, Germany University Hospital Mannheim, Neurology Clinic Not yet recruiting Mannheim, Germany University Hospital Regensburg, Neurology Clinic Not yet recruiting Regensburg, Germany University Hospital Tuebingen, Neurooncology Not yet recruiting Tübingen, Germany 收起 <<
NCT03087448	Non-small Cell Lung Cancer	Phase 1 Phase 2	Recruiting	March 2021	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 收起 <<
NCT03737994	ALK Gene Rearrangement ... 展开 >> ALK Positive Non-Squamous Non-Small Cell Lung Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 收起 <<	Phase 2	Not yet recruiting	December 13, 2025	-
NCT02314481	Non-small Cell Lung Cancer	Phase 2	Recruiting	January 2023	United Kingdom ... 展开 >> Univeristy College London Hospital Recruiting London, United Kingdom Contact: Amy Smith 收起 <<
NCT03178552	Non-Small Cell Lung Cancer	Phase 2 Phase 3	Recruiting	January 2, 2022	-
NCT02706626	Non-Small Cell Lung Cancer	Phase 2	Recruiting	January 2020	United States, Colorado ... 展开 >> University Of Colorado Recruiting Denver, Colorado, United States, 80045 Contact: Anna Wynfield 720-848-5278 anna.wynfield@ucdenver.edu Contact: Paula Fisk 720-848-0676 Paula.Fisk@ucdenver.edu Principal Investigator: David R Camidge, MD United States, North Carolina Duke University Recruiting Durham, North Carolina, United States, 27710 Contact: Debra Shoemaker, RN 919-681-4768 Debra.shoemaker@duke.edu Principal Investigator: Thomas E Stinchcombe, MD United States, Tennessee Vanderbilt Unversity Medical Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Kathy Taylor 615-875-0060 kathy.l.taylor@vanderbilt.edu Principal Investigator: Leora Horn, MD United States, Texas University of Texas, Southwestern Recruiting Dallas, Texas, United States, 75390 Contact: Jessica Saltarski 214-648-1688 Jessica.Saltarski@UTSouthwestern.edu Principal Investigator: David Gerber, MD 收起 <<
NCT03535740	ALK-positive Advanced NSCLC	Phase 2	Not yet recruiting	April 22, 2022	-
NCT02450903	Non-Small-Cell Lung Cancer	Phase 2	Completed	-	Japan ... 展开 >> Novartis Investigative Site Nagoya, Aichi, Japan, 464-8681 Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 811-1395 Novartis Investigative Site Akashi, Hyogo, Japan, 673-8558 Novartis Investigative Site Sakyo-ku, Kyoto, Japan, 606 8507 Novartis Investigative Site Natori, Miyagi, Japan, 981-1293 Novartis Investigative Site Okayama-city, Okayama, Japan, 700-8558 Novartis Investigative Site Sayama, Osaka, Japan, 589-8511 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0045 Novartis Investigative Site Koto-ku, Tokyo, Japan, 135 8550 收起 <<
NCT03546894	-		Recruiting	June 14, 2021	United States, Massachusetts ... 展开 >> EmpiraMed, Inc. Recruiting Maynard, Massachusetts, United States, 01754 收起 <<
NCT01981005	Healthy Volunteer	Phase 1	Completed	-	Netherlands ... 展开 >> Zuidlaren, Netherlands, 9471 GP 收起 <<
NCT01940510	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Austin, Texas, United States, 78744 收起 <<
NCT02091141	Neoplasms Sol... 展开 >>id Tumors Biliary Cancer Salivary Cancer Bladder Cancer 收起 <<	Phase 2	Recruiting	March 31, 2021	-
NCT02604342	Non-small Cell Lung Cancer	Phase 3	Completed	-	-
NCT02074553	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Austin, Texas, United States, 78744 收起 <<
NCT02074553	-		Completed	-	-
NCT02271139	-		-	-	-
NCT03155009	Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	May 28, 2020	France ... 展开 >> CHU Angers Active, not recruiting Angers, France, 49933 Hopital Jean Minjoz; Pneumologie Active, not recruiting Besancon, France, 25030 Hôpital Ambroise Paré - Boulogne-Billancourt Active, not recruiting Boulogne Billancourt, France, 92100 Hopital Augustin Morvan; Oncologie Thoracique Active, not recruiting Brest, France, 29609 Hopital Louis Pradel; Pneumologie Terminated Bron, France, 69677 Centre Francois Baclesse; Comite 3 Active, not recruiting Caen, France, 14076 Centre Hospitalier Intercommunal; Service de Pneumologie Active, not recruiting Creteil, France, 94010 Hôpital Nord Michallon; Pneumologie Active, not recruiting La Tronche, France, 38700 CHRU Lille Service de Pneumologie et Oncologie Thoracique Active, not recruiting Lille, France, 59000 Hôpital Universitaire Dupuytren Withdrawn Limoges, France, 87042 Hôpital Nord - AP-HM Marseille# Active, not recruiting Marseille, France, 13915 Hôpital Arnaud de Villeneuve Active, not recruiting Montpellier, France, 34295 Hopital Emile Muller;Pneumologie Active, not recruiting Mulhouse, France, 68070 Institut Curie Recruiting Paris, France, 75005 Hopital Tenon;Pneumologie Active, not recruiting Paris, France, 75970 CHU de Bordeaux Active, not recruiting Pessac, France, 33600 Hopital de Pontchaillou; Service de Pneumologie Active, not recruiting Rennes, France, 35033 CHU de Rouen - Hôpital Charles Nicolle Active, not recruiting Rouen, France, 76031 Hopital Civil; Pneumology Active, not recruiting Strasbourg, France, 67091 Hopital Sainte Musse; Pneumologie Active, not recruiting Toulon, France, 83056 CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique Active, not recruiting Toulouse cedex 9, France, 31100 Hopital Robert Schuman; Pneumologie Active, not recruiting Vantoux, France, 57070 收起 <<
NCT03456076	Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	September 30, 2026	-
NCT02023125	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Austin, Texas, United States, 78744 收起 <<
NCT01940510	-		Completed	-	-
NCT02023125	-		Completed	-	-
NCT03194893	Neoplasms	Phase 3	Recruiting	June 12, 2024	-
NCT02604342	-		Completed	-	-
NCT01984229	Healthy Volunteer	Phase 1	Completed	-	United States, Texas ... 展开 >> Austin, Texas, United States, 78744 收起 <<
NCT01984229	-		Completed	-	-
NCT02075840	Non-Small Cell Lung Cancer	Phase 3	Active, not recruiting	January 21, 2020	-
NCT01801111	-		Completed	-	-
NCT02013219	Non-Small Cell Lung Cancer	Phase 1	Active, not recruiting	January 18, 2019	United States, California ... 展开 >> UC Irvine Medical Center Orange, California, United States, 92868 United States, Connecticut Yale University School Of Medicine New Haven, Connecticut, United States, 06510 United States, Florida Florida Hospital Cancer Inst Orlando, Florida, United States, 32804 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts Massachusetts General Hospital;Hematology/ Oncology Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Med Ctr; Neurology/MS Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Center; Department of Oncology Detroit, Michigan, United States, 48201 United States, New York Memorial Sloan Kettering - Basking Ridge New York, New York, United States, 10065 United States, Ohio Case Western Reserve University; Medicine-Hematology and Oncology Cleveland, Ohio, United States, 44106 United States, South Carolina Greenville Health System Greenville, South Carolina, United States, 29605 France Institut Gustave Roussy Villejuif, France, 94805 Hong Kong The Chinese University of Hong Kong Shatin, Hong Kong, 123456 Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of, 03080 Asan Medical Center Seoul, Korea, Republic of, 05505 Spain START Madrid. Centro Integral Oncologico Clara Campal; CIOCC Madrid, Spain, 28050 Hospital Clinico Universitario de Valencia Valencia, Spain, 46010 United Kingdom Queen Mary University of London London, United Kingdom, EC1M 6BQ 收起 <<
NCT02838420	Anaplastic Lymphoma Kinase-pos... 展开 >>itive Non-small Cell Lung Cancer 收起 <<	Phase 3	Active, not recruiting	December 6, 2019	China ... 展开 >> Cancer Hospital Chinese Academy of Medical Sciences. Beijing, China, 100021 Beijing Cancer Hospital Beijing, China, 100142 Beijing Chest Hospital; Oncology Department Beijing, China, 101149 Jilin Cancer Hospital Changchun, China, 130012 the First Hospital of Jilin University Changchun, China, 130021 West China Hospital, Sichuan University Chengdu, China, 610041 Third Affiliated Hospital of Third Military Medical University ChongQing, China, 400042 Second Affiliated Hospital of Third Military Medical University Chongqing, China Sun Yet-sen University Cancer Center Guangzhou, China, 510060 Guangdong General Hospital Guangzhou, China, 510080 The First Affiliated Hospital of Guangzhou Medical University Guangzhou, China, 510120 The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, China, 310003 Zhejiang Cancer Hospital Hangzhou, China, 310022 Harbin Medical University Cancer Hospital Harbin, China, 150081 Jiangsu Cancer Hospital Nanjing, China, 210009 The Affiliated Hospital of Medical College Qingdao University Qingdao, China, 266003 Shanghai chest hospital Shanghai, China, 200030 Fudan University Shanghai Cancer Center Shanghai, China, 200032 Shanghai Pulmonary Hospital Shanghai, China, 200433 Korea, Republic of CHA Bundang Medical Center Gyeonggi-do, Korea, Republic of, 13496 Kangbuk Samsung Hospital Seoul, Korea, Republic of, 03181 Asan Medical Center Seoul, Korea, Republic of, 05505 Samsung Medical Center Seoul, Korea, Republic of, 6351 Thailand Rajavithi Hospital; Division of Medical Oncology Bangkok, Thailand, 10400 Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc Bangkok, Thailand, 10400 Khon Kaen University Khon Kaen, Thailand, 40002 Songklanagarind Hospital; Department of Internal Medicine, Division of Respiratory Songkhla, Thailand, 90110 收起 <<
NCT03596866	ALK-positive Advanced NSCLC	Phase 3	Not yet recruiting	September 4, 2023	-
NCT03131206	ALK-positive Non-small Cell Lu... 展开 >>ng Cancer (NSCLC) RET-positive Non-small Cell Lung Cancer (NSCLC) RET-positive Thyroid Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	May 1, 2020	United States, California ... 展开 >> University of California, Irvine Irvine, California, United States, 92697-7600 United States, Massachusetts Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01871805	Non-Small Cell Lung Cancer	Phase 1 Phase 2	Completed	-	-
NCT01801111	Non-Small-Cell Lung Carcinoma	Phase 1 Phase 2	Completed	-	-
NCT03202940	Non-small Cell Lung Cancer	Phase 1 Phase 2	Recruiting	August 30, 2020	United States, Massachusetts ... 展开 >> Massachusetts general Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Alice T Shaw, MD, PhD 617-643-0563 Ashaw1@partners.org Principal Investigator: Alice T Shaw, MD, PhD 收起 <<
NCT02521051	Non-Small Cell Lung Cancer (NS... 展开 >>CLC) 收起 <<	Phase 1 Phase 2	Recruiting	June 2022	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Justin L. Gainor, MD 617-724-4000 jgainor@partners.org Principal Investigator: Justin Gainor, MD Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02155 Contact: Daniel Costa, MD, PhD, MMSc 617-667-9236 dbcosta@bidmc.harvard.edu Principal Investigator: Daniel Costa, MD, PhD, MMSc 收起 <<
NCT03445000	Non-small Cell Lung Cancer ... 展开 >> Non-small Cell Lung Cancer Metastatic Non-small Cell Lung Cancer Recurrent 收起 <<	Phase 2	Recruiting	June 2023	Belgium ... 展开 >> Institut Jules Bordet Recruiting Brussels, Belgium Principal Investigator: Thierry Berghmans France Unicancer - Institut Bergonie Not yet recruiting Bordeaux, France Principal Investigator: Sophie Cousin Hospital Nord Not yet recruiting Marseille, France Principal Investigator: Laurent Greillier Gustave Roussy Not yet recruiting Villejuif, France Principal Investigator: Benjamin Besse Germany Klinikum Esslingen Not yet recruiting Esslingen, Germany Principal Investigator: Martin Faehling Uniklinik Frankfurt Not yet recruiting Frankfurt, Germany Principal Investigator: Martin Sebastian Universitätsklinikum Köln Not yet recruiting Köln, Germany Principal Investigator: Jürgen Wolf Thoracic Oncology Centre Munich Not yet recruiting München, Germany Principal Investigator: Huber Ireland St. James Hospital Not yet recruiting Dublin, Ireland Principal Investigator: Sinead Cuffe Italy IRCCS Instituto Tumori Giovanni Paolo II Not yet recruiting Bari, Italy Principal Investigator: Domenico Galetta Instituto Europeo di Oncologia (IEO) Recruiting Milano, Italy Principal Investigator: Filippo de Marinis University Hospital of Turin Not yet recruiting Turin, Italy Principal Investigator: Silvia Novello Universita di Verona Recruiting Verona, Italy Principal Investigator: Emilio Bria Netherlands The Netherlands Cancer Institute Amsterdam Not yet recruiting Amsterdam, Netherlands Principal Investigator: Egbert Smith University Medical Center Maastricht Not yet recruiting Maastricht, Netherlands Principal Investigator: Anne-Marie Dingemans Portugal IPO Porto Not yet recruiting Porto, Portugal Principal Investigator: Júlio Oliveira Slovenia Institute of Oncology Not yet recruiting Ljubljana, Slovenia Principal Investigator: Simona Borštnar Spain Hospital general de Alicante Recruiting Alicante, Spain Principal Investigator: Bartomeu Massutí Vall d'Hebron University Hospital Recruiting Barcelona, Spain, 08035 Principal Investigator: Enriqueta Felip, M.D. Hospital Quirón Dexeus Recruiting Barcelona, Spain Principal Investigator: Santiago Viteri Hospital Sant Pau Recruiting Barcelona, Spain Principal Investigator: Ivana Sullivan Hospital Teresa Herrara Recruiting La Coruna, Spain Contact: Rosario Garcia Campelo, MD MA.Rosario.Garcia.Campelo@sergas.es Hospital Puerta de Hierro Recruiting Madrid, Spain Contact: Mariano Provencio, MD mprovencio.ensayoclinico@gmail.com Hospital Universitario 12 de Octubre Recruiting Madrid, Spain Principal Investigator: Luis Paz Ares Hospital Regional Universitario Carlos Haya Recruiting Málaga, Spain Principal Investigator: Manuel Cobo Switzerland HFR Fribourg Recruiting Fribourg, Switzerland Principal Investigator: Daniel Betticher Hôpital Universitaire de Genève Recruiting Genève, Switzerland Principal Investigator: Alfredo Addeo UniversitatSpital Zurich Recruiting Zurich, Switzerland Contact: Christian Britschgi, MD christian.britschgi@usz.ch Principal Investigator: Christian Britschgi, MD 收起 <<
NCT02075840	-		Active, not recruiting	-	-
NCT03271554	-		Recruiting	June 30, 2020	Korea, Republic of ... 展开 >> Inje University Busan Paik Hospital Recruiting Busan, Korea, Republic of, 47392 Pusan National University Hospital Recruiting Busan, Korea, Republic of, 49241 Kosin University Gospel Hospital Not yet recruiting Busan, Korea, Republic of, 49267 Dongnam Institute of Radiological & Medical Sciences Recruiting Busan, Korea, Republic of Chungbuk National University Hospital Recruiting Cheongju-si, Korea, Republic of, 28644 Kyungpook National University Chilgok Hospital Recruiting Daegu, Korea, Republic of, 41404 Keimyung University Dongsan Medical Center Recruiting Daegu, Korea, Republic of, 41931 Daegu Catholic University Medical Center Not yet recruiting Daegu, Korea, Republic of, 42472 Yonsei University Wonju Severance Christian Hospital Not yet recruiting Gangwon-do, Korea, Republic of, 26426 Inje University Ilsan Paik Hospital Not yet recruiting Gyeonggi-do, Korea, Republic of, 10380 CHA Bundang Medical Center Recruiting Gyeonggi-do, Korea, Republic of, 13496 Hallym University Sacred Heart Hospital Recruiting Gyeonggi-do, Korea, Republic of, 14068 Pusan National University Yangsan Hospital Recruiting Gyeongsangnam-do, Korea, Republic of, 50612 Catholic Univ. of Incheon St.Mary's Hospital Recruiting Incheon, Korea, Republic of, 21431 Inha University Hospital Recruiting Incheon, Korea, Republic of, 22332 Chonnam National University Hwasun Hospital Recruiting Jeollanam-do, Korea, Republic of, 58128 Kangbuk Samsung Hospital Recruiting Seoul, Korea, Republic of, 03181 Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Gangdong Kyung Hee University Hospital Not yet recruiting Seoul, Korea, Republic of, 05278 Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Gangnam Severance Hospital Recruiting Seoul, Korea, Republic of, 06273 Ewha Womans University Mokdong Hospital Not yet recruiting Seoul, Korea, Republic of, 07985 Korea University Guro Hospital Recruiting Seoul, Korea, Republic of, 08308 Samsung Medical Center Recruiting Seoul, Korea, Republic of, 6351 收起 <<
NCT02621047	-		Completed	-	-
NCT01871805	-		Completed	-	-
NCT02621047	Hepatic Impairment	Phase 1	Completed	-	Czechia ... 展开 >> Pharmaceutical Research Associates CZ, s.r.o. Praha 7, Czechia, 170 00 Slovakia Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie Bratislava, Slovakia, 831 01 收起 <<

艾乐替尼 /Alectinib {[allProObj[0].p_purity_real_show]}

Alectinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Alectinib 质控信息

Alectinib 生物活性

Alectinib 细胞研究

Alectinib 动物研究

Alectinib 临床研究

Alectinib 实验方案

Alectinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

艾乐替尼 /Alectinib {[allProObj[0].p_purity_real_show]}

Alectinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Alectinib 质控信息

Alectinib 生物活性

Alectinib 细胞研究

Alectinib 动物研究

Alectinib 临床研究

Alectinib 实验方案

Alectinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Alectinib 纯度/质量文件产品仅供科研